Correction to: Scientific Reports https://doi.org/10.1038/srep09925, published online 20 April 2015

The Article contains an error in Figure 2, where incorrect images were used during the image assembly.

The correct Figure 2 and accompanying legend appear below.

Figure 2
figure 2

EGFR inhibitor was effective for triple WT MM cells. (A) Gefinitib (5 μM) exhibited moderate inhibition in NRAS WT myeloma cells but not in mutated cells; (B) Mutated NRAS was able to activate downstream effectors without EGFR signalling; (C) metabolic shift of NRAS WT myeloma cells (LP-1) treated or untreated with Gefitinib (5 μM) for 24 h. Heatmap showing top changed metabolites between groups (each column representing a replicate within group, n = 4). (D) MSEA showing significant change in metabolites within pentose phosphate pathway with (E) representative metabolite levels in LP-1 cells.